Although early-stage cervical cancer can be effectively treated with surgery or chemoradiotherapy, locally advanced, recurrent, or metastatic diagnoses have poor prognoses with current treatment options. Novel immuno-oncology, targeted, and combination approaches are improving outcomes for advanced disease, representing a shift in the standard of care. Join us for an on-demand video activity that brings together cervical cancer experts for a discussion on: the latest clinical efficacy and safety data of new and emerging immune-oncology agents developing biomarker-based, patient-specific treatment plans. Be sure to download the Individualized Cervical Cancer Treatment Planning Resource available as part of this program!
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/evolving-standard-care-immuno-oncology-agents-cervical-cancer
- Start Date: 2024-06-28 05:00:00
- End Date: 2024-06-28 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Merck (Any division) - Amount: 46500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest